Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.

Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K.

BMC Pulm Med. 2010 Feb 22;10:7. doi: 10.1186/1471-2466-10-7.

2.

Systematic review of cost and cost-effectiveness of different TB-screening strategies.

Nienhaus A, Schablon A, Costa JT, Diel R.

BMC Health Serv Res. 2011 Sep 30;11:247. doi: 10.1186/1472-6963-11-247. Review.

3.

Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.

Steffen RE, Caetano R, Pinto M, Chaves D, Ferrari R, Bastos M, de Abreu ST, Menzies D, Trajman A.

PLoS One. 2013 Apr 4;8(4):e59546. doi: 10.1371/journal.pone.0059546. Print 2013.

4.

Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.

Auguste P, Tsertsvadze A, Pink J, Court R, Seedat F, Gurung T, Freeman K, Taylor-Phillips S, Walker C, Madan J, Kandala NB, Clarke A, Sutcliffe P.

Health Technol Assess. 2016 May;20(38):1-678. doi: 10.3310/hta20380.

5.

Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers.

del Campo MT, Fouad H, Solís-Bravo MM, Sánchez-Uriz MA, Mahíllo-Fernández I, Esteban J.

Infect Control Hosp Epidemiol. 2012 Dec;33(12):1226-34. doi: 10.1086/668436. Epub 2012 Oct 25.

PMID:
23143360
6.
7.

Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.

de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH.

Arch Intern Med. 2009 Jan 26;169(2):179-87. doi: 10.1001/archinternmed.2008.524.

PMID:
19171815
8.
9.

Priorities for screening and treatment of latent tuberculosis infection in the United States.

Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr.

Am J Respir Crit Care Med. 2011 Sep 1;184(5):590-601. doi: 10.1164/rccm.201101-0181OC.

10.

Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.

Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y.

Int J Tuberc Lung Dis. 2010 Apr;14(4):471-81.

PMID:
20202306
11.

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E.

Clin Vaccine Immunol. 2011 Dec;18(12):2102-8. doi: 10.1128/CVI.05299-11. Epub 2011 Oct 12.

12.

Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.

Kowada A, Takasaki J, Kobayashi N.

J Hosp Infect. 2015 Feb;89(2):99-108. doi: 10.1016/j.jhin.2014.10.002. Epub 2014 Oct 24.

PMID:
25559158
13.

Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts.

Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S.

Eur Respir J. 2010 Jun;35(6):1346-53. doi: 10.1183/09031936.00098509. Epub 2009 Oct 19.

14.

Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.

O'Shea MK, Fletcher TE, Beeching NJ, Dedicoat M, Spence D, McShane H, Cunningham AF, Wilson D.

PLoS One. 2014 May 9;9(5):e97366. doi: 10.1371/journal.pone.0097366. eCollection 2014.

15.

Cost-effectiveness of tobacco cessation support combined with tuberculosis screening among contacts who smoke.

Kowada A.

Int J Tuberc Lung Dis. 2015 Jul;19(7):857-63. doi: 10.5588/ijtld.14.0518.

PMID:
26056114
16.

Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.

Oxlade O, Schwartzman K, Menzies D.

Int J Tuberc Lung Dis. 2007 Jan;11(1):16-26.

PMID:
17217125
17.

Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.

Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola RA, Hill PC.

BMC Infect Dis. 2007 Oct 25;7:122.

18.

Cost-effectiveness of interferon-gamma release assays for tuberculosis screening in nursing homes.

Kowada A.

Epidemiol Infect. 2016 Nov;144(15):3215-3225. Epub 2016 Jul 14.

PMID:
27412626
19.

Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis.

Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, Lalvani A, Kon OM.

Thorax. 2013 Mar;68(3):230-9. doi: 10.1136/thoraxjnl-2011-201542. Epub 2012 Jun 12.

PMID:
22693179
20.

Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan.

Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, Fukui T.

Mol Diagn Ther. 2008;12(4):235-51.

PMID:
18652520

Supplemental Content

Support Center